The All Wales Medicines Strategy Group started the assessment of ivacaftor (Kalydeco) as soon as the drug company formally engaged with the appraisal process. This process is recognised to be robust and normally takes about 21 weeks to allow all parties, including patient organisations such as the Cystic Fibrosis Trust, to submit their comments. The final appraisal decision for Kalydeco is scheduled to be reached at a public meeting on 8th May 2013.
More top news
Police say they want "no surprises" from Welsh football fans.
Assembly's Presiding Officersays Neil Hamilton’s use of sexist language last week is unacceptable.
As the search is called off for three missing men, the family of Christopher Huxtable say it is not right.